6 results about "RNase H" patented technology

The present invention describes that a pre-mRNA molecule, which temporarily exists before polyadenylation-site induced cleavage occurs, can be targeted by RNase H recruiting antisense oligonucleotides downstream of a transcripts 3' terminus to reduce expression levels of target genes from which the RNA polymerization originates.

The application belongs to the technical field of biological detection, and relates to a miRNAs quantitative detection kit based on probe connection and a detection method. The detection kit comprises a first probe, a second probe, a primer F, a primer R, a reaction enzyme and magnetic beads. The reaction enzyme comprises a Splint-R ligase and an RNase H enzyme. The miRNA to be detected is miRNA159, miRNA122 or miRNA24. According to the target to be detected, the application designs a responding probe sequence, and has the advantages of fast detection speed, short measurement time, high connection efficiency, high sensitivity and strong specificity.

The present invention relates to a bioswitchable, embedded miRNA-loaded tetrahedral framework nucleic acid, and a preparation method therefor and the use thereof. In the present invention, miRNA is embedded into a tetrahedral framework nucleic acid (tFNA), and a ribonucleotide is extended at the end of each miRNA strand as a biological switch. Such enzyme-responsive biological switches can be triggered by intracellular RNase H to realize the disassembly of a three-dimensional structure. Moreover, the miRNA comprises a toehold-mediated strand displacement domain, which facilitates the binding of miRNA to an intracellular target, thereby achieving specific cell recognition. The miRNA delivery platform provided by the present invention can effectively treat tumors such as uveal melanoma, and diseases such as acute liver injuries and acute kidney injuries.

This invention discloses a method and kit for isothermal cascade amplification melting curve analysis to detect RNA. The method includes designing a first primer, a second primer, a circular amplification probe, and a detection probe based on the sequence of the circular amplification probe. Isothermal amplification is performed in an amplification system containing the first primer, the second primer, the circular amplification probe, the detection probe, the sample, a nicking enzyme, RNA-dependent DNA polymerase, ribonuclease H, RNA polymerase, and strand displacement polymerase. This invention ingeniously combines an isothermal detection system, RNA polymerase-mediated transcription amplification technology, and a melting curve analysis system, avoiding the heating delay caused by the large heat capacity of the metal module in traditional thermal cyclers, thus significantly reducing the required time and enabling rapid detection.

The application provides a preparation method and application of an anti-L1CAM antibody drug conjugate, the anti-L1CAM antibody drug conjugate comprising an anti-L1CAM single-chain antibody, a DNA / RNA hybrid chain molecule and a cytotoxin DM1; the anti-L1CAM single-chain antibody is covalently connected to one end of the DNA / RNA hybrid chain molecule; the cytotoxin DM1 is covalently connected to the other end of the DNA / RNA hybrid chain molecule; and the DNA / RNA hybrid chain molecule comprises an RNase H sensitive segment. The technical scheme of the application specifically couples the anti-L1CAM single-chain antibody and the DM1 through the DNA / RNA hybrid chain, so that the obtained antibody drug conjugate integrates targeting, intelligent release and high-efficiency killing, has the effect of inhibiting retinoblastoma proliferation, and can effectively inhibit retinoblastoma proliferation and metastasis.